Your Navigation:PCAR > Abstract
Search pcar
检索项:
检索词:
Abstract
Pharmaceutical Care and Research: 2019; 19(4):280-283,303
DOI: 10.5428/pcar20190411
Risk of malignancy in patients with diabetes treated with glargine: a meta analysis
1. HUANG Wenhui1(1.Department of Pharmacy,No.909 Hospital of Joint Logistics Support Force/Southeast Hospital Affiliated to Xiamen University,Fujian Zhangzhou 363000,China hwhui175@163.com)
2. WEN Huiping2(2.Department of Gastroenterology,No.909 Hospital of Joint Logistics Support Force/Southeast Hospital Affiliated to Xiamen University,Fujian Zhangzhou 363000,China )
3. CHEN Shu1(1.Department of Pharmacy,No.909 Hospital of Joint Logistics Support Force/Southeast Hospital Affiliated to Xiamen University,Fujian Zhangzhou 363000,China )
4. XUE Honglin1(1.Department of Pharmacy,No.909 Hospital of Joint Logistics Support Force/Southeast Hospital Affiliated to Xiamen University,Fujian Zhangzhou 363000,China asctx472@126.com)
ABSTRACT  Objective: To systematically evaluate the relationship between glargine and malignancy in diabetes patients.Methods: The databases,such as PubMed,the databases of China National Knowledge Infrastructure(CNKI),Wanfang Data,China Science and Technology Journal Database(VIP) were retrived from the inception to February 2018.The literature was selected according to Cochrane Collaboration system review.After data collection and quality evaluation,meta analysis was performed using RevMan 5.3 software.Results: A total of 16 randomized controlled trials(RCTs) were included in the study.Results of meta analysis showed that the risk of malignancy in the glargine group was similar to that of the placebo or other hypoglycemic agents groups,without statistical significance[RR=0.98, 95%CI(0.83,1.16),P=0.80]. Further research found that the risk of breast cancer, colorectal cancer and prostate cancer in the glargine group was also similar to that of the placebo or other hypoglycemic agents group(P>0.05).Conclusion: Glargine did not increase the risk of malignancy including breast cancer,colorectal cancer and prostate cancer in diabetes patients.
Welcome to PCAR! You are the number 70 reader of this article!
Please cite this article as:
HUANG Wenhui1,WEN Huiping2,CHEN Shu1,XUE Honglin1,. Risk of malignancy in patients with diabetes treated with glargine: a meta analysis[J]. Pharmaceutical Care and Research / yao xue fu wu yu yan jiu. 2019; 19(4): 280-283,303.
References:
1. LIU Yunhui,HOU Liqiong,ZHAO Tieyun,et al.Efficacy and safety of glargine insulin injection Uslen versus Lantus in diabetic patients:a multicenter,randomized,open-labeled controlled trial[J].Chin J Diab Mellitus,2014,6(6):377-381.In Chinese with English abstract.
2. Mayer D,Shukla A,Enzmann H.Proliferative effects of insulin analogues on mammary epithelial cells[J].Arch Physiol Biochem,2008,114(1):38-44.
3. Weinstein D,Simon M,Yehezkel E,et al.Insulin analogues display IGF-Ⅰ-like mitogenic and anti-apoptotic activities in cultured cancer cells[J].Diab Metab Res Rev,2009,25(1):41-49.
4. Hemkens L G,Grouven U,Bender R,et al.Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues:a cohort study[J].Diabetologia,2009,52(9):1732-1744.
5. Colhoun H M,SDRN Epidemiology Group.Use of insulin glargine and cancer incidence in Scotland:a study from the Scottish Diabetes Research Network Epidemiology Group[J].Diabetologia,2009,52(11):1755-1765.
6. Currie C J,Poole C D,Gale E A.The influence of glucose-lowering therapies on cancer risk in type 2 diabetes[J].Diabetologia,2009,52(9):1766-1777.
7. The Cochrane Collaboration. Cochrane handbook for systematic reviews of interventions (version 5.1.0)[EB/OL].(2011-03)[2018-03-01]. http://handbook-5-1.cochrane.org/.
8. Aschner P,Chan J,Owens D R,et al.Insulin glargine versus sitagliptin in insulin-naive patients with type 2 diabetes mellitus uncontrolled on metformin(EASIE):a multicentre,randomised open-label trial[J].Lancet,2012,379(9833):2262-2269.
9. Blicklé J F,Hancu N,Piletic M,et al.Insulin glargine provides greater improvements in glycaemic control vs. intensifying lifestyle management for people with type 2 diabetes treated with OADs and 7%-8% A1c levels.The TULIP study[J].Diabetes Obes Metab,2009,11(4):379-386.
10. Blonde L,Jendle J,Gross J,et al.Once-weekly dulaglutide versus bedtime insulin glargine,both in combination with prandial insulin lispro, in patients with type 2 diabetes (AWARD-4):a randomised, open-label, phase 3,non-inferiority study[J].Lancet,2015,385(9982):2057-2066.
11. Bowering K,Reed V A,Felicio J S,et al.A study comparing insulin lispro mix 25 with glargine plus lispro therapy in patients with type 2 diabetes who have inadequate glycaemic control on oral anti-hyperglycaemic medication:results of the PARADIGM study[J]. Diabet Med,2012,29(9):e263-e272.
12. The ORIGIN Trial Investigators.Basal insulin and cardiovascular and other outcomes in dysglycemia[J].N Engl J Med,2012,367(4):319-328.
13. Giorgino F,Benroubi M,Sun J H,et al.Efficacy and safety of once-weekly dulaglutide versus insulin glargine in patients with type 2 diabetes on metformin and glimepiride (AWARD-2)[J].Diabetes Care,2015,38(12):2241-2249.
14. Gough S C,Bhargava A,Jain R,et al.Low-volume insulin degludec 200 units/ml once daily improves glycemic control similarly to insulin glargine with a low risk of hypoglycemia in insulin-naive patients with type 2 diabetes:a 26-week,randomized, controlled, multinational,treat-to-target trial:the BEGIN LOW VOLUME trial[J]. Diabetes Care,2013,36(9):2536-2542.
15. Heller S,Buse J,Fisher M,et al.Insulin degludec,an ultra-longacting basal insulin,versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1):a phase 3,randomised,open-label, treat-to-target non-inferiority trial[J].Lancet,2012, 379(9825):1489-1497.
16. Meneghini L,Atkin S L,Gough S C,et al.The efficacy and safety of insulin degludec given in variable once-daily dosing intervals compared with insulin glargine and insulin degludec dosed at the same time daily:a 26-week,randomized,open-label,parallel-group, treat-to-target trial in individuals with type 2 diabetes[J]. Diabetes Care,2013,36(4):858-864.
17. PAN Changyu,Gross J L,YANG Wenying,et al.A multinational,randomized,open-label,treat-to-target trial comparing insulin degludec and insulin glargine in insulin-naive patients with type 2 diabetes mellitus[J].Drugs R D,2016,16(2):239-249.
18. Rosenstock J,Fonseca V,McGill J B,et al.Similar risk of malignancy with insulin glargine and neutral protamine Hagedorn(NPH) insulin in patients with type 2 diabetes: findings from a 5 year randomised, open-label study[J].Diabetologia,2009,52(9):1971-1973.
19. Weissman P N,Carr M C,Ye J,et al.HARMONY 4:randomised clinical trial comparing once-weekly albiglutide and insulin glargine in patients with type 2 diabetes inadequately controlled with metformin with or without sulfonylurea[J].Diabetologia,2014,57(12):2475-2484.
20. YANG Wenying,XU Xiangjin,LIU Xiaomin,et al.Treat-to-target comparison between once daily biphasic insulin aspart 30 and insulin glargine in Chinese and Japanese insulin-naive subjects with type 2 diabetes[J]. Curr Med Res Opin,2013,29(12):1599-1608.
21. Garber A J,King A B,Del Prato S,et al.Insulin degludec, an ultra-longacting basal insulin,versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2):a phase 3,randomised,open-label, treat-to-target non-inferiority trial[J].Lancet,2012,379(9825):1498-1507.
22. Marso S P,McGuire D K,Zinman B,et al.Efficacy and safety of degludec versus glargine in type 2 diabetes[J].N Engl J Med,2017,377(8):723-732.
23. Rodbard H W,Cariou B,Zinman B,et al.Comparison of insulin degludec with insulin glargine in insulin-naive subjects with type 2 diabetes: a 2-year randomized, treat-to-target trial[J].Diabet Med,2013,30(11):1298-1304.
24. LIU Lianyong,WANG Jingnan,GU Mingjun.Glargine and cancer[J].Pharm Care Res,2010,10(6):458-460.In Chinese with English abstract.
25. Kurtzhals P,Schffer L,Srensen A,et al.Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use[J].Diabetes,2000,49(6):999-1005.
《药学服务与研究》杂志社 All Rights Reserved 网站备案号:鲁B2-20061008
·地址:上海市杨浦区长海路168号18号楼东三楼 邮政编码:200433
·联系电话(传真):86-21-65519829, 021-31162330
·电子邮件:PharmCR@vip.163.com
·技术支持:中国康网
管理员入口